May 8, 2017
Ipsen buys five Sanofi’s products
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 8, 2017
IDMC gives green light for extension of Faron Pharmaceuticals’s rare lung disease
Faron Pharmaceuticals has received the Independent Data Monitoring Committee’s (IDMC) recommendation to continue the INTEREST Phase III study for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) with its lead product Traumakine.
May 8, 2017
MT Pharma America accepts ALS challenge – wins FDA approval
Its have been three years since Ice bucket challenge went viral promoting awareness of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease and encourage donations to research.
May 5, 2017
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
MDxHealth has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics.
May 5, 2017
Genfit enrolls first patients in its liver disease drug test
Genfit, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, has started patient testing in the Phase 2a trial evaluating elafibranor in PBC.
May 5, 2017
Tetraphase Pharmaceutical reports $29.5M for Q1 2017
Tetraphase Pharmaceutical has reported a net loss of $29.5 million for the first quarter of 2017 which is decrease compared to a net loss of $16.7 million for the same period in 2016.
May 4, 2017
FDA takes Pfizer’s sNDA for psoriatic arthritis drug
United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).
May 4, 2017
Karo Pharma reaches second milestone from collaboration with Pfizer
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.
May 4, 2017
argnex half through myasthenia gravis drug study
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has recruited 50% of the myasthenia gravis (MG) patients in the Phase 2 proof-of-concept study of ARGX-113.
May 4, 2017
Mereo BioPharma starts Phase 2 study of rare bone disease drug
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has initiated a potentially pivotal Phase 2b clinical study of BPS-804 for the treatment of the orphan disease, osteogenesis imperfecta (OI) (brittle bone disease), the ASTEROID study.